

**Oncology Today with Dr Neil Love: Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Edition****THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

- 1. Which of the following is the target of the various chimeric antigen receptor (CAR) T-cell therapies under evaluation for patients with multiple myeloma (MM)?**
  - a. CD19
  - b. BCMA**
  - c. CD20
- 2. Which of the following is true regarding the management of severe cytokine release syndrome (CRS) experienced by patients receiving CAR T-cell therapy?**
  - a. Tocilizumab is the only effective agent
  - b. Corticosteroids are the only effective therapy
  - c. Both tocilizumab and corticosteroids are effective**
- 3. Which of the following is true with regard to patients with relapsed/refractory MM undergoing treatment with anti-BCMA CAR-T therapy?**
  - a. There is a direct correlation between experiencing CRS and benefit from the CAR T-cell therapy
  - b. Patients who experience CRS in addition to those with no such symptoms benefit from treatment with CAR T-cell therapy**
- 4. The novel, next-generation anti-BCMA CAR T-cell product bb21217 has a similar construct to that of idecabtagene vicleucel (bb2121) but differs in that it is cultured with which of the following class of agents in order to enrich the product's duration of response?**
  - a. Anti-PD-1/PD-L1 antibody
  - b. IMiD (immunomodulatory agent)
  - c. PI3k inhibitor**